Canine adenoviral vector-mediated gene transfer to the guinea pig brain

Pre-clinical testing of gene transfer tools is often first conducted in small animal models such as laboratory mice or rats, before extension into a larger animal such as non-human primates. The guinea pig brain may provide an intermediary model in which to examine neurodevelopmental processes given that guinea pigs are considered precocial. Here, we characterized the efficacy and biodistribution following injection of a canine adenovirus type 2 (CAV-2) vector in the young adult guinea pig brain. Despite the development of mild fevers post-treatment in the vector-treated animals, widespread transduction was evident throughout the brain parenchyma. Neutralizing antibodies against CAV-2 were not detected. Our data demonstrate that the combination of CAV-2 vectors and guinea pigs provide a clinically relevant model for evaluation of therapeutics.